Evaluation of [18F]MK-6240 binding to tau protein in postmortem human brains of Down syndrome and Alzheimer’s disease and assessment of off-target (non-tau) binding
Open Access
- 14 March 2026
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Abstract
Alzheimer's disease (AD) and Down Syndrome (DS) are characterized by the aggregation of tau tangles. As a novel tau PET tracer in AD, [ 18 F]MK-6240 has the potential in Down syndrome-associated Alzheimer’s disease (DSAD) to elucidate pathophysiology and advance diagnostic strategies. Autoradiography of frontal cortex and temporal cortex postmortem brain slices of DSAD (n = 5), AD (n = 5), and cognitively normal (CN) (n = 5) cases indicated similarly high [ 18 F]MK-6240 binding in DSAD and AD cases. [ 18 F]MK-6240 binding in CN was substantially less than DSAD and AD. Anti-tau immunostains confirmed total tau presence that aligned with the localization of [ 18 F]MK-6240 binding. DSAD and AD cases exhibited higher gray matter (GM)/white matter ratios of 2.8 and 2.5 respectively. For drug effects on [ 18 F]MK-6240 binding, self-displacement by MK-6240 (10 µM) reduced binding by 88% among DSAD cases and 85% among AD cases while IPPI (10 µM) displaced [ 18 F]MK-6240 by 81% and 74% in DSAD and AD cases respectively. KuFal194 (10 µM), a specific phosphokinase inhibitor, minimally displaced [ 18 F]MK-6240 binding. Harmine competed with [ 18 F]MK-6240 with an IC 50 value of 290 nM and 92 nM for DSAD and AD cases, respectively. High meninges off-target (non-tau) binding of [ 18 F]MK-6240 was observed in a CN case, comparable to the GM in DSAD and AD. MK-6240 (10 µM) blocked 44% and T807 (10 µM) blocked 30% of meninges binding. Incubation of meninges in the presence of 0.2% polyethyleneimine reduced 70% of [ 18 F]MK-6240 binding. The tau radioligand, [ 125 I]IPPI, an analog of [ 18 F]MK-6240, exhibited minimal binding to CN meninges compared to the DSAD and AD cases. Our findings suggest [ 18 F]MK-6240 to be selective tau imaging agent in DSAD and AD, harmine to uniquely compete with [ 18 F]MK-6240 binding in DSAD and provide preliminary insights to the off-target nonspecific binding of [ 18 F]MK-6240 in postmortem meninges.Keywords
All Related Versions
Funding Information
- National Institutes of Health (R01AG077700)
This publication has 84 references indexed in Scilit:
- Comparing Off‐Target Meningeal and Skull Signal in Head‐to‐Head MK‐6240 and AV‐1451 Tau PETAlzheimer's & Dementia, 2025
- Higher off‐target meninges [F‐18]MK6240 PET signal associated with APOE4 carriageAlzheimer's & Dementia, 2025
- Cortical tau aggregation drives axonal degeneration in white matter fiber tracts in Alzheimer’s diseaseAlzheimer's & Dementia, 2024
- Characterizing the emergence of amyloid and tau burden in Down syndromeAlzheimer's & Dementia, 2023
- Longitudinal investigation for enhancing Down Syndrome Research (LIFE‐DSR) Study: Tau PET and CSF sub‐studiesAlzheimer's & Dementia, 2021
- Development and evaluation of [125I]IPPI for Tau imaging in postmortem human Alzheimer's disease brainSynapse, 2020
- Tau PET Imaging for Staging of Alzheimer's Disease in Down SyndromeDevelopmental Neurobiology, 2018
- cGMP production of the radiopharmaceutical [18F]MK‐6240 for PET imaging of human neurofibrillary tanglesJournal of Labelled Compounds and Radiopharmaceuticals, 2017
- Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissueAnnals of Neurology, 2015
- Impairment of paravascular clearance pathways in the aging brainAnnals of Neurology, 2014